Treatment of gastrointestinal acute graft-versus-host disease

Current Treatment Options in Gastroenterology

Volumn 8, Issue 3, 2005, Pages 249-258

  Ross, William A ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICONVULSIVE AGENT; ANTIFUNGAL AGENT; ANTIVIRUS AGENT; BUDESONIDE; CORTICOSTEROID; CYCLOSPORIN; CYTOCHROME P450 3A4; DACLIZUMAB; DENILEUKIN DIFTITOX; ECHINACEA EXTRACT; GASTROINTESTINAL AGENT; IMMUNOMODULATING AGENT; IMMUNOSUPPRESSIVE AGENT; INFLIXIMAB; LIVE VACCINE; MACROLIDE; METHOXSALEN; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; ORAL CONTRACEPTIVE AGENT; RAPAMYCIN; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; STEROID; TACROLIMUS; THYMOCYTE ANTIBODY; TUBERCULOSTATIC AGENT;

ABDOMINAL PAIN; ACNE; ACUTE GRAFT VERSUS HOST DISEASE; ADRENAL SUPPRESSION; ANEMIA; AVASCULAR NECROSIS; BONE DEFECT; CAPILLARY LEAK SYNDROME; CATARACT; CHILL; CLINICAL TRIAL; CONSTIPATION; CYTOMEGALOVIRUS INFECTION; DEPRESSION; DIAPHORESIS; DIARRHEA; DRUG COST; DRUG DOSE REGIMEN; DRUG HYPERSENSITIVITY; DRUG MEGADOSE; DYSPNEA; EUPHORIA; FEVER; FLU LIKE SYNDROME; FLUID RETENTION; FOOD DRUG INTERACTION; GASTROINTESTINAL DISEASE; GLAUCOMA; HEADACHE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEMATURIA; HERPES; HIRSUTISM; HUMAN; HYPERCHOLESTEROLEMIA; HYPERGLYCEMIA; HYPERKALEMIA; HYPERLIPIDEMIA; HYPERTENSION; HYPOALBUMINEMIA; HYPOKALEMIA; HYPOPHOSPHATEMIA; HYPOTENSION; IMMUNE DEFICIENCY; IMMUNOSUPPRESSIVE TREATMENT; INFECTION; INFECTION RATE; INSOMNIA; IRRITABILITY; KIDNEY FAILURE; KIDNEY TUBULE NECROSIS; LEUKOPENIA; LIVER DISEASE; MALIGNANT NEOPLASTIC DISEASE; MOON FACE; MYOPATHY; NAUSEA; OSTEOPENIA; OSTEOPOROSIS; PHOTOCHEMOTHERAPY; RESPIRATORY TRACT INFECTION; REVIEW; SEPSIS; SIDE EFFECT; SKIN DISEASE; THROMBOCYTOPENIA; THROMBOTIC THROMBOCYTOPENIC PURPURA; TUBERCULOSIS; URINARY TRACT INFECTION; VOMITING; WOUND HEALING IMPAIRMENT;

EID: 21044443017     PISSN: 10928472     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11938-005-0017-9     Document Type: Review

References (60)

1. Tabbara IA, Zimmerman K, Morgan C, Nahleh Z: Allogenic hematopoietic stem cell transplantation. Arch Int Med 2002, 162:1558-1566.
2. Nash RA, Pepe MS, Storb R, et al.: Acute graft-versus-host disease: analysis of risk factors after allogenic marrow transplantation and prophylaxis with cyclosporine and methotrexate. Blood 1992, 80:1838-1845.
3. Przepiorka D, Smith TL, Folloder J, et al.: Risk factors for acute graft-versus-host disease after allogenic blood stem cell transplantation. Blood 1999, 94:1465-1470.
4. Vogelsang GB, Lee L, Bensen-Kennedy DM: Pathogenesis and treatment of graft-versus-host disease after bone marrow transplantation. Ann Rev Med 2003, 54:29-52.
5. Couriel D, Caldera H, Champlin R, Komanduri K: Acute graft-versus-host disease: pathophysiology, clinical manifestations, and management. Cancer 2004, 101:1936-1946.
6. Akpek G, Chinratanalab W, Lee LA, et al.: Gastrointestinal involvement in chronic graft-versus-host disease: a clinicopathologic study. Biol Blood Marrow Transpl 2003, 9:46-51.
7. Ratanatharathorn V, Ayash L, Lazarus HM, et al.: Chronic graft-versus-host disease: clinical manifestations and therapy. Bone Marrow Transpl 2001, 28:121-129.
8. Higman MA, Vogelsang GB: Chronic graft-versus-host disease. Br J Haematol 2004, 125:435-454.
9. Cutler C, Giri S, Jeyapalan S, et al.: Acute and chronic graft-versus-host disease after allogenic peripheral blood stem cell and bone marrow transplantation: a meta-analysis. J Clin Oncol 2001, 19:3685-3691.
10. Schmitz N, Beksac M, Hasenclever D, et al.: Transplantation of mobilized peripheral blood cells to HLA-identical siblings with standard risk leukemia. Blood 2002, 100:761-767.
11. Champlin RE, Schmitz N, Horowitz MM, et al.: Blood stem cells compared with bone marrow as a source of hematopoietic cells for allogenic transplantation. Blood 2000, 95:3702-3709.
12. Bacigalupo A, Palandri F: Management of acute graft versus host disease. Hematol J 2004, 5:189-196.
13. Couriel DR, Saliba RM, Giralt S, et al.: Acute and chronic graft-versus-host disease after ablative and nonmyeloablative conditioning for allogenic hematopoietic transplantation. Biol Blood Marrow Transpl 2004, 10:178-185.
14. Martin PJ, McDonald GB, Sanders JE, et al.: Increasingly frequent diagnosis of acute gastrointestinal graft-versus-host disease after allogenic hematopoietic cell transplantation. Biol Blood Marrow Transpl 2004, 10:320-327.
15. Hill GR, Ferrara JLM: The primacy of the gastrointestinal tract as a target organ of acute graft-versus-host disease: rationale for the use of cytokine shields in allogenic bone marrow transplantation. Blood 2000, 95:2754-2759.
16. Przepiorka D, Weisdorf D, Martin P, et al.: Consensus conference on acute GVHD grading. Bone Marrow Transpl 1995, 15:825-828.
17. Gratwohl A, Hermans J, Apperley J, et al.: Acute graft-versus-host disease: grade and outcome in patients with chronic myelogenous leukemia. Blood 1995, 86:813-818.
18. LeBlanc K, Ringden O, Remberger M: A low body mass index is correlated with poor survival after allogenic stem cell transplantation. Haematologica 2003, 88:1044-1052.
19. Doherty J, Zahurak M, Margolis J, et al.: Chronic graft-versus-host disease and severe weight loss. Blood 1999, 94 [Suppl 1]:A696.
20. Jacobsohn DA, Margolis J, Doherty J, et al.: Weight loss and malnutrition in patients with chronic graft-versus-host disease. Bone Marrow Transpl 2002, 29:231-236.
21. Nash RA, Antin JH, Karanes C, et al.: Phase 3 study comparing methotrexate and tacrolimus with methotrexate and cyclosporine for prophylaxis of acute graft-versus-host disease after marrow transplantation from unrelated donors. Blood 2000, 9:2062-2068.
22. Martin PJ, Schoch G, Fisher L, et al.: A retrospective analysis of therapy for acute graft-versus-host disease: initial treatment. Blood 1990, 76:1464-1472.
23. Hings JM, Severson R, Filipovich AH, et al.: Treatment of moderate and severe acute graft-versus-host disease after allogenic bone marrow transplantation. Transplant 1994, 58:437-442.
24. MacMillan ML, Weisdorf DJ, Wagner JE, et al.: Response of 443 patients to steroids as primary therapy for acute graft-versus-host disease: comparison of grading systems. Biol Blood Marrow Transpl 2002, 8:387-394.
25. McDonald GB, Bouvier M, Hockenbery DM, et al.: Oral beclomethasone dipropionate for treatment of intestinal graft-versus-host disease: a randomized, controlled trial. Gastro 1998, 115:28-35.
26. Bertz H, Afting M, Kreisel W, et al.: Feasibility and response to busdesonide as topical corticosteroid therapy for acute intestinal graft-versus-host disease. Bone Marrow Transpl 1999, 24:1185-1189.
27. Hsu B, May R, Carrum G, et al.: Use of anti-thymocyte globulin for treatment of steroid-refractory acute graft-versus-host disease: an international practice survey. Bone Marrow Transpl 2001, 28:945-950.
28. Graziani F, Van Lint MT, Dominietto A, et al.: Treatment of acute graft-versus-host disease with low-dose, alternate day antithymocyte globulin. Haematologica 2002, 87:973-978.
29. Martin PJ, Schoch G, Fisher L, et al.: A retrospective analysis of therapy for acute graft-versus-host disease: secondary treatments. Blood 1991, 77:1821-1828.
30. Antin JH, Chen AR, Couriel DR, et al.: Novel approaches to the therapy of steroid-resistant acute graft-versus-host disease. Biol Blood Marrow Transpl 2004, 10:655-668.
31. MacMillan ML, Weisdorf DJ, Davies SM, et al.: Early anti-thymocyte globulin therapy improves survival in patients with steroid-resistant acute graft-versus-host disease. Biol Blood Marrow Transpl 2002, 8:40-46.
32. Arai S, Margolis J, Zahurak M, et al.: Poor outcome in steroid-refractory graft-versus-host disease with antithymocyte globulin treatment. Biol Blood Marrow Transpl 2002, 8:155-160.
33. Remberger M, Aschan J, Barkholt L, Tollemar J, Ringden O: Treatment of severe acute graft-versus-host disease with anti-thymocyte globulin. Clin Transpl 2001, 15:147-53.
34. Khoury H, Kashyap A, Adkins DR, et al.: Treatment of steroid-resistant acute graft-versus-host disease with anti-thymocyte globulin. Bone Marrow Transpl 2001, 27:1059-1064.
35. Jacobsohn DA: Emerging therapies for graft-versus-host disease. Expert Opin Emerging Drugs 2003, 8:323-338.
36. Benito AI, Furlong T, Martin PJ, et al.: Sirolimus (rapamycin) for the treatment of steroid-refractory acute graft-versus-host disease. Transpl 2001, 72:1924-1928.
37. Couriel DR, Hicks K, Saliba R, et al.: Sirolimus (rapamycin) for treatment of steroid-refractory chronic graft-versus-host disease. Biol Blood Marrow Transpl 2003, 9:67-68.
38. Cutler C, Li S, Kim HT, et al.: Sirolimus and tacrolimus as graft-vs.-host disease prophylaxis in allogenic stem cell transplantation: the Dana-Farber Cancer Institute experience. Blood 2004, 104 [Suppl 1]:346a.
39. Ho VT, Zahrieh D, Hochberg E, et al.: Safety and efficacy of denileukin diftitox in patients with steroid-refractory acute graft-versus-host disease after allogenic hematopoietic stem cell transplantation. Blood 2004, 104:1224-1226.
40. Srinivasan R, Chakrabarti S, Walsh T, et al.: Improved survival in steroid-refractory acute graft-versus-host disease after non-myeloablative allogenic transplantation using daclizumab-based strategy with comprehensive infection prophylaxis. Br J Haematol 2004, 124:777-786.
41. Weisser M, Goede V, Schiel X, Kolb HJ: Steroid refractory GVHD of the gut can be treated effectively with daclizumab and sirolimus. Blood 2004, 104 [Suppl 1]:349a.
42. Couriel DR, Saliba R, Hicks K, et al.: Tumor necrosis factor alpha blockade for the treatment of steroid-refractory acute GVHD. Blood 2004, 104:649-654.
43. Patriarca F, Sperotto A, Damiani D, et al.: Infliximab treatment for steroid-refractory acute graft-versus-host disease. Haematologica 2004, 89:1352-1359.
44. Marty FM, Lee SJ, Fahey MM, et al.: Infliximab use in patients with severe graft-versus-host disease and other emerging risk factors of non-Candida invasive fungal infections in allogenic hematopoietic stem cell transplant recipients: a cohort study. Blood 2003, 102:2768-2776.
45. Everitt DE: Important drug warning. http:/www.fda.gov/medwatch/SAFETY/2004/remicade_DHCP_dec04.pdf Accessed January 15, 2005.
46. Prezepiorka D, Kernan NA, Ippoliti C, et al.: Daclizumab, a humanized anti-interleukin-2 receptor alpha chain antibody, for treatment of acute graft-versus-host disease. Blood 2000, 95:83-89.
47. Willenbacher W, Basara N, Blau IW, et al.: Treatment of steroid refractory acute and chronic graft-versus-host disease with daclizumab. Br J Haematol 2001, 112:820-823.
48. Lee SJ, Zahrich D, Agura E, et al.: Effect of up-front daclizumab when combined with steroids for the treatment of acute graft-versus-host disease: results of a randomized trial. Blood 2004, 104:1559-1564.
49. Baudard M, Vincent A, Moreau P, et al.: Mycophenolate mofetil for the treatment of acute and chronic GVHD is effective and well tolerated but induces a high risk of infectious complications: a series of 21 BM and PSC transplant patients. Bone Marrow Transpl 2002, 30:287-295.
50. Basara N, Kiehl MG, Blau W, et al.: Mycophenolate mofetil in the treatment of acute and chronic graft-versus-host disease in hematopoietic stem cell transplant patients: four years of experience. Transpl Proc 2001, 33:2121-2123.
51. Kim JG, Sohn SK, Kim DH, et al.: Different efficacy of mycophenolate mofetil as salvage treatment for acute and chronic GVHD after allogenic stem cell transplant. Eur J Haematol 2004, 73:56-61.
52. Barrett AJ, Rezvani K, Solomon S, et al.: New developments in allotransplant immunology. Hematology (Am Soc Hematol Educ Program) 2003, 350-371.
53. Barry FP, Murphy JM: Mesenchymal stem cells: clinical applications and biological characterization. Int J Biochem Cell Biol 2004, 36:568-584.
54. LeBlanc K, Rasmussen I, Sundberg B, et al.: Treatment of severe graft-versus-host disease with third party haploidentical mesenchymal stem cells. Lancet 2004, 363:1439-1441.
55. Frassoni F, Labopin M, Bacigalupo A, et al.: Expanded mesenchymal stem cell (MSC) re-infused with HLA identical HSC transplants reduce acute and chronic graft-versus-host disease: a matched pair analysis. Bone Marrow Transpl 2002, 29 [Suppl 1]:S2.
56. Furlong T, Leisenring W, Storb R, et al.: Psoralen and ultraviolet A irradiation (PUVA) as therapy for steroid-resistant cutaneous acute graft-versus-host disease. Biol Blood Marrow Transpl 2002, 8:206-212.
57. Grenix HT, Volc-Platzer B, Kaths P, et al.: Extracorporeal photochemotherapy in the treatment of steroid-refractory acute graft-versus-host disease: a pilot study. Blood 2000, 96:2426-431.
58. Lee S, Dorken B, Schmitt D: Extracorporeal photopheresis in graft-versus-host disease: ultraviolet radiation mediates T cell senescence in vivo. Transpl 2004, 78:484-485.
59. Messina C, Locateli F, Lanino E, et al.: Extracorporeal photochemotherapy for paediatric patients with graft-versus-host disease after haematopoietic stem cell transplantation. Br J Haematol 2003, 122:118-127.
60. Gorgun G, Miller KB, Foss FM: Immunologic mechanisms of extracorporeal photochemotherapy in chronic graft-versus-host disease. Blood 2002, 100:941-947. x